03/24/2025
6:57 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Flynn James E (Filed by)
| Form SCHEDULE 13D/A | |
03/21/2025
5:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Karas Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/20/2025
3:03 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Karas Eric (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/20/2025
3:05 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/20/2025
6:02 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/20/2025
6:04 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/07/2025
4:12 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Shawver Laura (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/05/2025
4:18 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/05/2025
4:19 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/04/2025
3:35 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Shawver Laura (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/03/2025
11:06 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
Get the Latest News and Ratings for SBTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Silverback Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
01/31/2025
4:21 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form S-3ASR | |
01/13/2025
7:08 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/07/2025
5:24 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Shawver Laura (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/06/2025
3:36 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/19/2024
3:20 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/19/2024
3:20 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
6:52 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
6:53 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
4:24 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/12/2024
4:41 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/12/2024
4:02 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/11/2024
5:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/11/2024
5:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/11/2024
4:31 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Dorsey Brian (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
3:48 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
10:15 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Lowenthal Richard E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/09/2024
4:43 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/09/2024
4:25 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/09/2024
11:38 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Shawver Laura (Reporting)
| Form 144/A | |
12/06/2024
6:15 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/06/2024
4:30 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/05/2024
4:06 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/03/2024
4:25 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
6:01 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
5:22 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
3:42 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Karas Eric (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/27/2024
3:11 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/21/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/21/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/15/2024
2:21 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
Trump’s betrayal exposed (Ad) Trump’s Final Reset
Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now. Millions of Americans are about to be wiped out, while others could make a fortune… click here to ma |
11/13/2024
7:16 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
DEERFIELD MANAGEMENT COMPANY, L.P. (0001009258) (Reporting)
Deerfield Mgmt III, L.P. (Reporting)
Deerfield Mgmt IV, L.P. (Reporting)
Deerfield Private Design Fund III, L.P. (Reporting)
Deerfield Private Design Fund IV, L.P. (Reporting)
Flynn James E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/13/2024
6:02 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/13/2024
6:00 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/17/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Scott Kathleen D. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/16/2024
3:01 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Scott Kathleen D. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/15/2024
10:28 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Tanimoto Sarina (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/15/2024
6:02 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/10/2024
3:27 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/10/2024
3:28 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/23/2024
3:15 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/19/2024
3:26 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/19/2024
3:29 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/19/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Karas Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/18/2024
3:06 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Karas Eric (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/12/2024
3:24 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/12/2024
3:25 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/10/2024
9:31 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Lowenthal Richard E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/28/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Thompson Peter A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/23/2024
5:41 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Thompson Peter A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/23/2024
5:38 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
ORBIMED ADVISORS LLC (Reporting)
OrbiMed Capital GP VI LLC (Reporting)
ORBIMED CAPITAL LLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:43 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
ORBIMED CAPITAL LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/21/2024
5:47 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:48 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:49 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Scott Kathleen D. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:51 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Karas Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:51 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/20/2024
3:18 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Scott Kathleen D. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/15/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/15/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/15/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/12/2024
6:59 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/18/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/18/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
11:07 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Tanimoto Sarina (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/11/2024
4:03 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/11/2024
4:04 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/28/2024
2:15 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/28/2024
5:46 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/24/2024
4:06 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Dadoo Rajeev (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/24/2024
4:13 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/21/2024
4:00 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/17/2024
7:47 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Pratik Shah Living Trust dated June 15, 2011 (Filed by)
| Form SC 13D/A | |
06/17/2024
5:39 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Shah Pratik (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/13/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/11/2024
6:18 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Pratik Shah Living Trust dated June 15, 2011 (Filed by)
| Form SC 13D/A | |
06/11/2024
10:36 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Lowenthal Richard E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/07/2024
8:09 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Pratik Shah Living Trust dated June 15, 2011 (Reporting)
Shah Pratik (Reporting)
| Form 4/A | |
06/07/2024
8:11 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Shah Pratik (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Trump’s Final Plan (Ad) Presidential insider exposes shocking plot to reshape U.S. economy:
The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed. Click here for the full story. |
06/06/2024
3:32 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Pratik Shah Living Trust dated June 15, 2011 (Reporting)
Shah Pratik (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
6:51 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
6:52 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/10/2024
6:01 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/09/2024
5:57 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2024
5:59 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2024
3:08 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/24/2024
5:17 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/24/2024
5:18 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
